Summer 2027
Liability Management & Restructuring Summer Associate Intern
Restructuring & Debt Advisory
Posted on 9/9/2026
Evercore
1,001-5,000 employees
Global independent investment banking advisory
Compensation Overview
$88.94/hr
Company Does Not Provide H1B Sponsorship
New York, NY, USA
In Person
MBA, JD
 Finance & Banking (1) |
|---|
Get referred to Evercore
See people who can refer or advise you
- Be a current First Year Master of Business Administration student from a top business school or current second-year law student from a top law school.
- Have several years of relevant work experience.
- Have a strong grasp of corporate finance, valuation, and financial accounting.
- Demonstrate superior analytical skills and excellence in academic coursework.
- Have excellent interpersonal skills and the ability to articulate ideas.
- Have outstanding written and oral communication skills.
- Demonstrate a strong interest in investment banking, solid quantitative and analytical skills, and the ability to think broadly about strategic issues confronting clients.
- Prepare for and attend client meetings.
- Perform financial modeling.
- Resolve complex accounting and financial issues.
- Analyze financial statements, credit documents, valuations, industries, and competitors.
- Conduct due diligence and assist with new business development.
- Manage analysts.
- Oversee financial and valuation analysis.
- Draft client presentations.
- Manage and execute live deal situations.
- Manage relationships with law firms, consultants, accounting firms, creditors, and other investment banks involved in transactions.
- Work on in-court and out-of-court restructurings and recapitalizations, exchanges, tenders, liability management transactions, distressed mergers and acquisitions, and non-syndicated capital raises.
- Demonstrate sound judgment and intellectual curiosity.
- Have a great work ethic.
- Have an enthusiastic, outgoing, and achievement-oriented character.
Evercore is a global independent investment banking advisory firm that helps clients with strategic and financial decisions. Its services include advice on mergers and acquisitions, divestitures, and restructuring, as well as capital raising for public and private markets. The firm also provides equity research, equity sales, and agency trading execution, and offers wealth and investment management. With offices in major financial centers across North America, Europe, South America, the Middle East, and Asia, Evercore often works on high-profile deals. The company differentiates itself through its independence, broad range of advisory and capital markets services, and global reach, aiming to help clients achieve their strategic and financial objectives.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
New York City, New York
Founded
1995
Get referred to Evercore
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 underwriting fees jumped 201% to $97 million, doubling deal count.
- Healthcare, industrials, and ECM hiring in 2026 broadened mandate coverage across regions.
- Citgo auction work and Vantage's $2 billion financing showcase complex, fee-rich mandates.
What critics are saying
- Citgo litigation now questions Evercore's conflicts, threatening fees and reputational damage through 2026.
- Evercore's partnership depends on rainmakers; losing star bankers quickly hurts revenue.
- A deal freeze would crush advisory and underwriting, exposing Evercore's cyclical earnings model.
What makes Evercore unique
- Evercore's Q2 2026 advisory fees hit a record $776 million.
- It added 19 senior managing directors year-to-date, including John Pissanos and defense bankers.
- Its independent model spans M&A, restructuring, and capital raising without lending conflicts.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
Mental Health Support
Family Planning Benefits
Paid Holidays
Paid Vacation
Paid Sick Leave
Paid Personal Leave
Paid Parental Leave
Company News
Vantage, a global digital infrastructure provider, has closed a $2 billion financing facility to support early-stage development across its North American platform. The five-year revolving credit facility includes an initial collateral pool of three development assets, with the option to add more over time. The facility aims to provide committed capital as demand for data centres continues to grow, strengthening Vantage's ability to fund projects and deliver capacity quickly. Evercore and Wells Fargo Securities served as lead arrangers for the transaction, which included a dozen insurance and institutional investors. The facility is part of Vantage's broader capital strategy. The company has closed more than $40 billion of capital this year to support global growth and diversify funding sources.
GE Aerospace strikes $11.75 billion CPP casting deal. Key moments. * GE Aerospace agreed to acquire Consolidated Precision Products for $11.75 billion from Warburg Pincus and Berkshire Partners. * The deal values CPP at about 18 times expected 2027 EBITDA including synergies, and about 26 times without synergies. * The transaction is expected to close in the second half of 2027 and to be accretive to adjusted EPS and free cash flow in the first year. Strategic move to expand casting capacity. Investing.com - GE Aerospace announced Tuesday that it has entered into a definitive agreement to acquire Consolidated Precision Products (CPP) from private equity owners Warburg Pincus and Berkshire Partners in a transaction valued at $11.75 billion. CPP is a supplier of engineered castings and sub-assemblies that serve both commercial aerospace and defense end markets. GE Aerospace Chairman and CEO H. Lawrence Culp, Jr. said the planned acquisition is intended to address the need for additional casting capacity to support demand across commercial engines, aftermarket activity, and defense programs. He indicated that pairing GE Aerospace's technology with CPP's manufacturing base is expected to increase capacity and accelerate the development of engine technologies. CPP's manufacturing footprint and capabilities. CPP, headquartered in Cleveland, Ohio, manufactures investment and precision sand castings used in commercial and military aircraft, weapon systems, jets, helicopters, and industrial gas turbines. Its portfolio spans complex super alloy, titanium, aluminum, magnesium, and steel cast components. The company employs approximately 6,600 people across more than 20 facilities. Founded in 1991, CPP is described as one of the world's largest producers of investment and precision sand castings. GE Aerospace has been a customer of CPP for more than fifteen years. Deal Valuation and financing structure. The agreement values CPP at approximately 18 times projected 2027 EBITDA when expected net synergies are included, and at approximately 26 times 2027 EBITDA excluding synergies. | Metric | Detail | | Total transaction value | $11.75 billion | | Valuation multiple (with synergies) | Approximately 18x 2027 EBITDA | | Valuation multiple (without synergies) | Approximately 26x 2027 EBITDA | | Cash financing | $7 billion | | Remaining consideration | Funded with new debt | GE Aerospace plans to fund $7 billion of the purchase price with cash, with the balance to be financed through new debt issuance. The company stated that the acquisition is expected to be accretive to adjusted earnings per share and free cash flow in the first year after closing. GE Aerospace also said that its capital allocation plans will remain unchanged as a result of the transaction. Closing timeline and advisory teams. The companies expect the transaction to close in the second half of 2027, subject to regulatory approvals and other customary closing conditions. Evercore and PJT Partners are acting as lead financial advisors to GE Aerospace. Morgan Stanley and Guggenheim Securities are advising CPP on the deal.
Evercore appoints John Pissanos as healthcare Senior Managing Director. * September 1, 2026 Investment banking giant Evercore has officially appointed John Pissanos as a Senior Managing Director. He joins the global firm's growing healthcare investment banking group. Moreover, Pissanos will operate directly out of the London office. His core professional focus targets medtech along with life science tools and diagnostics. The strategic hire reflects the commitment of Evercore to scale its international advisory franchise. Consequently, this executive move enhances sector expertise throughout Europe, the Middle East, and Africa. "We are delighted to welcome John to Evercore," said Giuseppe Monarchi, co-head of Evercore's EMEA investment banking business. "John is a highly regarded healthcare banker with deep relationships across the sector and a strong track record advising clients on some of their most important strategic transactions. His extensive expertise across life science tools & diagnostics and medtech in particular further strengthens and expands our healthcare franchise and reinforces our continued investment in expanding our capabilities and serving clients across EMEA." Proven investment banking leadership. Mr. Pissanos brings nearly 15 years of high-level experience in the financial industry to Evercore. Previously, he built a distinguished career at J.P. Morgan. He most recently served there as Managing Director and Head of EMEA Life Science Tools & Diagnostics. Therefore, his deep operational insight brings strong advisory depth to Evercore clients. His academic achievements add to his credentials as a professional. Pissanos has an MBA from London Business School. He also holds an M.Sc. from the University of Reading. He completed his B.S. at the Georgia Institute of Technology. Mr. Pissanos said, "I am excited to join Evercore's healthcare investment banking team. Evercore has built one of the leading global healthcare investment banking franchises, and I look forward to working alongside colleagues across the firm's international platform to continue delivering exceptional advice and outcomes for our clients." Furthermore, Evercore continues to prioritize top-tier talent acquisition across crucial global markets. The addition of Pissanos enables Evercore to capture expanding market share within European healthcare advisory sectors. Also, such an executive appointment allows Evercore to leverage the rising trend of cross-border M&A in the European medical technology and diagnostics industries. As regulations change and the need for innovation in the healthcare industry increases within the EMEA region, Pissanos will play an essential role in extending the client base and driving strategic advisory deals. In the end, his appointment will help to solidify Evercore's strategy of becoming an industry leader and providing comprehensive financial advisory services in growing verticals. For more stories on technology leaders shaping the future of enterprise solutions, visit its CXO Insiders.
The Pipeline: commercial real estate roundup for 8.28.26. #1 Irving Properties purchased 4.6 acres at 1800 Oak Lake Boulevard in Chesterfield for $900,000 from Oaklake II LLC. Colton Konvicka with Commonwealth represented the buyer. #2 1617 W Broad Street LLC purchased 3,739 square feet at 1617 W. Broad St. in Richmond for $775,000 from Southlake Group. Nathan Hughes with Sperity Real Estate Ventures represented the buyer. TOP THREE LEASES #1 Spirit Halloween Superstore leased 40,000 square feet at 44-100 Southpark Boulevard in Colonial Heights. Alicia Brown and Pete Waldbauer with Cushman & Wakefield | Thalhimer represented the landlord. #2 Mad House RVA leased 9,608 square feet at 3405 Carlton St. in Richmond. Betsy Mangum with Sperity Real Estate Ventures represented the tenant. #3 Evercore Partners Services East leased 7,984 square feet at 919 E. Main St. in Richmond. Gray Bryant with Colliers represented the tenant. Email submissions to [email protected] Cushman & Wakefield | Thalhimer reports the following deals: KidStrong leased 4,000 square feet at 13700 Hull Street Road in Chesterfield. David Crawford and James Ashby IV represented the landlord. Homecure leased 1,753 square feet at 7443 Lee Davis Road in Mechanicsville. Amy J. Broderick, Kate Hosko and Richard L. Thalhimer represented the landlord. Sperity Real Estate Ventures reports the following deals: Bare Pro Academy leased 1,439 square feet at 1112-A W Main Street in Richmond. Betsy Mangum represented the tenant. Virginia Lice Removal leased 1,206 square feet at 1500 Huguenot Road, Suite 106, in Chesterfield. Betsy Mangum represented the tenant. Beauty & Brains LLC leased 3,903 square feet at 1322 W. Broad St. in Richmond. Nathan Hughes represented the landlord. Mossy Road Counseling leased 1,040 square feet at 4914 Radford Avenue, Suite 206, in Henrico. Veronica Wiles represented the tenant. Rising Stars Academy subleased 3,067 square feet at 7511 Brook Road in Henrico. Veronica Wiles represented the sublessor. The Ministry leased 1,100 square feet of at 2400 Venable St. in Richmond. Nathan Hughes represented the landlord. 1617 W Broad Street LLC purchased 3,739 square feet at 1617 W. Broad St. in Richmond for $775,000 from Southlake Group. Nathan Hughes represented the buyer. Joy Blooms leased 2,476 square feet at 1420-D Hull St. in Richmond. Betsy Mangum represented the tenant. Commonwealth reports the following deals: Legacy Family & Behavioral Health Services leased 1,745 square feet at 5511 Staples Mill Road, Suite 204, in Henrico. Sam Edwards represented the tenant. Homemade Hustle leased 968 square feet at 825 Grove Road, Suite 10, in Chesterfield County. Liz Gray represented the landlord. M&A Shark LLC leased 1,020 square feet at 13543 Midlothian Turnpike in Chesterfield. Liz Gray, Todd Buttner and Hartley Jordan represented the landlord. Irving Properties purchased 4.6 acres at 1800 Oak Lake Boulevard in Chesterfield for $900,000 from Oaklake II LLC. Colton Konvicka represented the buyer. Colliers reports the following deals: Eurofins Lancaster Laboratories Environment Testing subleased 5,814 square feet at 5500 Cox Road in Henrico. Jimmy Martin represented the landlord. Gilman Rolfing leased 570 square feet at 7113 Three Chopt Road in Henrico. Catherine Walker represented the landlord. Bryan Davis leased 1,356 square feet at 8100 Three Chopt Road in Henrico. Gray Bryant and John Carpin represented the landlord.
Correction: Entera to participate in upcoming fall investor conferences. TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) - Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that the Company's Chief Executive Officer, Miranda Toledano, will be participating in the following upcoming fall investor conferences: 2026 Cantor Global Healthcare Conference Fireside Chat: September 10, 2026 at 1:00 p.m. Eastern Time, Waldorf Astoria New York, 301 Park Avenue, New York, NY Guggenheim Securities 3rd Annual Healthcare Innovation Conference November 9, 2026, Fireside Chat and 1x1 Meetings, Location: Boston, MA Evercore ISI 9th Annual Healthcare Conference November 30-December 2, 2026, in person, Location: Miami, FL About Entera Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages a disruptive and proprietary technology platform (N-Tab(R) and its pipeline of first-in-class oral peptide programs. The Company's most advanced product candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet for osteoporosis. A placebo-controlled, dose-ranging Phase 2 study of EB613 tablets (n = 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is also developing the first oral Long Acting PTH(1-34) tablet as a replacement therapy for patients with hypoparathyroidism (EB612), the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide tablet for the treatment of obesity and metabolic syndromes; and the first oral GLP-2 tablet as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health, Inc. For more information on Entera, visit www.enterabio.com or follow us on LinkedIn, Twitter, and Facebook. Cautionary Statement Regarding Forward Looking Statements Various statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy, clinical development activities, collaboration arrangements and expected financial and operational results are forward-looking statements. Words such as, but not limited to, "anticipate," "believe," "can," "could," "expect," "estimate," "design," "goal," "intend," "may," "might," "objective," "plan," "predict," "project," "target," "likely," "should," "will," and "would," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Important factors that could cause actual results to differ materially from those reflected in Entera's forward-looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA's interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera's product candidates; Entera's reliance on third parties to conduct its clinical trials; Entera's ability to establish and maintain development and commercialization collaborations; Entera's operation as a development stage company with limited operating history; Entera's competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories it pursues; Entera's ability to continue as a going concern absent access to sources of liquidity; Entera's ability to obtain and maintain regulatory approval for any of its product candidates; Entera's ability to comply with Nasdaq's minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera's intellectual property position and its ability to protect its intellectual property; and other factors that are described in the "Cautionary Statement Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Entera's most recent Annual Report on Form 10-K filed with the SEC, as well as Entera's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward-looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward-looking statements Entera makes in this press release. The information in this press release is provided only as of the date of this press release, and Entera undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law. Company Contact: [email protected]